Elan, Abbott End Ranbaxy Suit Over Generic TriCor

Law360, New York (February 28, 2011, 7:40 PM EST) -- Elan Pharma International Ltd. and Abbott Laboratories on Friday ended a patent infringement suit in New Jersey over Ranbaxy Inc.'s plans to introduce a generic version of cholesterol drug TriCor.

Judge Garrett E. Brown of the U.S. District Court for the District of New Jersey issued an order closing the case.

The order dismissed without prejudice infringement claims lodged by Elan and Fournier Laboratories Ireland Ltd., an Abbott subsidiary. The two sides also agreed to toss Ranbaxy's counterclaims that the patents-in-suit were invalid.

Neither side admitted...
To view the full article, register now.